These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

37 related articles for article (PubMed ID: 23905772)

  • 1. Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: incidence, mortality and clinical characterization.
    Yoshizawa K; Mukai HY; Miyazawa M; Miyao M; Ogawa Y; Ohyashiki K; Katoh T; Kusumoto M; Gemma A; Sakai F; Sugiyama Y; Hatake K; Fukuda Y; Kudoh S
    Cancer Sci; 2014 Feb; 105(2):195-201. PubMed ID: 24329927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib-induced Sweet's syndrome confirmed by rechallenge.
    Zobniw CM; Saad SA; Kostoff D; Barthel BG
    Pharmacotherapy; 2014; 34(4):e18-21. PubMed ID: 24338786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib-induced Sweet syndrome.
    Knoops L; Jacquemain A; Tennstedt D; Theate I; Ferrant A; Van den Neste E
    Br J Haematol; 2005 Oct; 131(2):142. PubMed ID: 16197442
    [No Abstract]   [Full Text] [Related]  

  • 4. Bortezomib-induced histiocytoid Sweet syndrome.
    Murase JE; Wu JJ; Theate I; Cole GW; Barr RJ; Dyson SW
    J Am Acad Dermatol; 2009 Mar; 60(3):496-7. PubMed ID: 19231647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Images in clinical Medicine. Bortezomib-induced skin lesions.
    Agterof MJ; Biesma DH
    N Engl J Med; 2005 Jun; 352(24):2534. PubMed ID: 15958809
    [No Abstract]   [Full Text] [Related]  

  • 6. [Bortezomib-induced acute neutrophilic dermatosis].
    Tanguy-Schmidt A; Avenel-Audran M; Croué A; Lissandre S; Dib M; Zidane-Marinnes M; Moles MP; Hunault-Berger M
    Ann Dermatol Venereol; 2009 May; 136(5):443-6. PubMed ID: 19442803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sweet-like syndrome induced by bortezomib.
    Kolb-Mäurer A; Kneitz H; Goebeler M
    J Dtsch Dermatol Ges; 2013 Dec; 11(12):1200-2. PubMed ID: 23905772
    [No Abstract]   [Full Text] [Related]  

  • 8. Distinct variant of Sweet's syndrome: bortezomib-induced histiocytoid Sweet's syndrome in a patient with multiple myeloma.
    Kim JS; Roh HS; Lee JW; Lee MW; Yu HJ
    Int J Dermatol; 2012 Dec; 51(12):1491-3. PubMed ID: 22998496
    [No Abstract]   [Full Text] [Related]  

  • 9. Sweet-like lesions induced by bortezomib: a review of the literature and a report of 2 cases.
    Truchuelo M; Bagazgoitia L; Alcántara J; Velasco D; Carrillo R
    Actas Dermosifiliogr; 2012 Nov; 103(9):829-31. PubMed ID: 22652505
    [No Abstract]   [Full Text] [Related]  

  • 10. Bortezomib in multiple myeloma.
    Mateos MV; San Miguel JF
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
    Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.